Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Mitoxantrone

Known as: 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9, 10-anthroquinone, 1,4-DIHYDROXY-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-anthracenedione, Mitoxantronum 
An anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA… Expand
National Institutes of Health

Related topics

Related topics

49 relations

Broader (2)

Antineoplastic Agentsanthracene

Narrower (26)

BBR 2577BBR3378CL 232315DMV regimen
Expand
Congestive heart failureIn BloodMammary NeoplasmsMitoxantrone Hydrochloride
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
BACKGROUND Cabazitaxel is a novel tubulin-binding taxane drug with antitumour activity in docetaxel-resistant cancers. We aimed… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.
PURPOSE The TAX 327 study compared docetaxel administered every 3 weeks (D3), weekly docetaxel (D1), and mitoxantrone (M), each… Expand
  • figure 1
  • table 1
  • figure 2
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
BACKGROUND Mitoxantrone plus prednisone reduces pain and improves the quality of life in men with advanced, hormone-refractory… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
BACKGROUND Mitoxantrone-based chemotherapy palliates pain without extending survival in men with progressive androgen-independent… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
A distinct "side population" of cells with high drug efflux capacity in human tumor cells.
A subset of stem cells, termed the "side population" (SP), has been identified in several tissues in mammalian species. These… Expand
  • table 1
  • figure 2
  • figure 4
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial
BACKGROUND Treatment options for patients with secondary progressive multiple sclerosis are few. Encouraging results in open… Expand
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes.
Reports of multiple distinct mitoxantrone-resistant sublines without overexpression of P-glycoprotein or the multidrug-resistance… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.
PURPOSE Approximately 40,000 men die each year of hormone-refractory prostate cancer (HRPC). The results of treatment with… Expand
Is this relevant?
Highly Cited
1998
Highly Cited
1998
A multidrug resistance transporter from human MCF-7 breast cancer cells.
MCF-7/AdrVp is a multidrug-resistant human breast cancer subline that displays an ATP-dependent reduction in the intracellular… Expand
Is this relevant?
Highly Cited
1996
Highly Cited
1996
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
PURPOSE To investigate the benefit of chemotherapy in patients with symptomatic hormone-resistant prostate cancer using relevant… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE